期刊全稱 | Atypical Antipsychotics | 影響因子2023 | Bart A. Ellenbroek,Alexander R. Cools | 視頻video | http://file.papertrans.cn/165/164936/164936.mp4 | 學科分類 | Milestones in Drug Therapy | 圖書封面 |  | 影響因子 | The introduction of chlorpromazine in 1953, and haloperidol in 1958, into clinical practice dramatically altered the therapy of schizophrenic patients. Although representing by no means a cure for this severe psychiatric ill- ness, it allowed, for the first time, to adequately control the severe hallu- cinations and delusional beliefs which prevent these patients from leading a more or less independent life. Indeed these antipsychotics (and the many congeners that were to follow) significantly reduced the number ofchronic schizophrenic inpatients in psychiatric clinics all over the world. However soon after their introduction it became clear that, like all other available drugs, antipsychotics were by no means miracle drugs. In fact, two major problems appeared. First, the antipsychotics had very little effect on the so-called negative or defect symptoms, like social isolation, apathy and anhedonia, and secondly virtually all antipsychotics produced a number of side-effects, of which the neurological (often called extra- pyramidal) side-effects were the most troublesome. Especially the tardive dyskinesia, which occurred in about 15 to 20% of the patients after pro- longed treatment | Pindex | Book 2000 |
The information of publication is updating
|
|